INVITED RESEARCH HIGHLIGHT
Year : 2014  |  Volume : 16  |  Issue : 3  |  Page : 413-414

Long-term survival of participants in the prostate cancer prevention trial


1 Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana, USA
2 Department of Urology and Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA

Correspondence Address:
Oliver Sartor
Department of Urology and Medicine, Tulane University School of Medicine, New Orleans, Louisiana
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.122868

Rights and Permissions

The Prostate Cancer Prevention Trial (PCPT) is a seminal study in the field of urology. More than 10 years after its initial publication, updated data from this trial continue to shape our understanding of prostate cancer. Among the major findings from the PCPT has been the demonstration that prostate cancer is common in men with prostate-specific antigen (PSA) once thought to be in the normal range, [1] finasteride prevents the development of benign prostatic hypertrophy, [2] it increases the sensitivity of PSA [3] and digital rectal examination. [4] Furthermore the PCPT helped to establish the link between erectile dysfunction and cardiovascular disease, [5] and perhaps most importantly finasteride demonstrated a 25% relative risk reduction in the diagnosis of prostate cancer compared with placebo. [6]


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1630    
    Printed70    
    Emailed0    
    PDF Downloaded316    
    Comments [Add]    
    Cited by others 1    

Recommend this journal